Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933489 · ClinicalTrials.gov registry record · NA
Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts
A NA study of Asymptomatic, sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 1,516
- Enrollment target
- 20
- Study locations
NCT02933489: Active NA study of Asymptomatic, sponsored by ECOG-ACRIN Cancer Research Group.
NCT02933489 is a NA study of Asymptomatic that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 1,516 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933489, a NA study of Asymptomatic, is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,516 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful magnet linked to a computer and used to create detailed pictures of the breast in less than 10 minutes. These pictures can show the difference between normal and diseased tissue. Digital tomosynthesis mammography is a procedure that uses multiple x-rays pictures of each breast to produce a 3-dimensional rendering of the entire breast. Combined screening with abbreviated breast MRI and digital tomosynthesis mammography may be a better method to screen women with dense breasts.
Primary Outcome
For each modality, the detection rate of invasive cancers is defined as the proportion of participants who had an invasive cancer detected by the modality at baseline and verified by pathology versus the total number of participants. In the out come measures table below, these proportions will be automatically calculated, multiplied by 100, and be presented as percentages (%).
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DIAGNOSTIC_TEST Contrast-enhanced Magnetic Resonance Imaging
- DIAGNOSTIC_TEST Digital Tomosynthesis Mammography
Study Locations (20)
Illinois
- Northwestern University - Chicago
- University of Chicago Comprehensive Cancer Center - Chicago
- NorthShore University HealthSystem-Evanston Hospital - Evanston
- Clinical Radiologists SC - Springfield
Florida
- Boca Raton Regional Hospital - Boca Raton
- Mayo Clinic in Florida - Jacksonville
- Diagnostic Center for Women LLC - Miami
Colorado
- The Women's Imaging Center - Denver
- Radiology Imaging Associates - Englewood
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- The Community Hospital - Munster
Kansas
- University of Kansas Cancer Center - Kansas City
- University of Kansas Hospital-Westwood Cancer Center - Westwood
Arizona
- Banner MD Anderson Cancer Center - Gilbert
California
- Huntington Memorial Hospital - Pasadena
Connecticut
- Norwalk Hospital - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,516 participants |
| Start Date | 2016-12-27 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
What the registry record for NCT02933489 still lists
NCT02933489 is an interventional study that assigns participants to a tested intervention. Its 1,516 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 1 condition, with Asymptomatic appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02933489 names 20 study sites across 12 states, led by Illinois, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT02933489 about?
NCT02933489 is a clinical study titled "Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts". This randomized phase II trial studies how well abbreviated breast magnetic resonance imaging (MRI) and digital tomosynthesis mammography work in detecting cancer in women with dense breasts. Abbreviated breast MRI is a low cost procedure in which radio waves and a powerful magnet linked to a comput...
What is the current status of trial NCT02933489?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,516 participants. The study started on 2016-12-27. Estimated completion is 2026-12-31.
What conditions does trial NCT02933489 study?
This clinical trial studies the following conditions: Asymptomatic.
What interventions are being tested in trial NCT02933489?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Contrast-enhanced Magnetic Resonance Imaging (DIAGNOSTIC_TEST), Digital Tomosynthesis Mammography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02933489?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02933489 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02933489's enrollment target sits among peer trials
1,516 65th of 2000 higher than 1,936 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05633654 · 1,514 participants · Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- NCT07136623 · 1,513 participants
Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope
- NCT07232017 · 1,520 participants
Implementation of Intensive Hypertension Management Approaches: Cleveland Clinic
- NCT06876714 · 1,524 participants · Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI